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Nasopharyngeal carcinoma (NPC) is a multifactorial malignancy closely associated with genetic factors and Epstein-Barr virus infection.
To identify the common genetic variants linked to NPC susceptibility, we conducted a genome-wide association study (GWAS) in 277
NPC patients and 285 healthy controls within the Taiwanese population, analyzing 480,365 single-nucleotide polymorphisms (SNPs).
Twelve statistically signiﬁcant SNPs were identiﬁed and mapped to chromosome 6p21.3. Associations were replicated in two indepen-
dent sets of case-control samples. Two of the most signiﬁcant SNPs (rs2517713 and rs2975042; pcombined ¼ 3.93 1020 and 1.63 1019,
respectively) were located in the HLA-A gene. Moreover, we detected signiﬁcant associations between NPC and two genes: speciﬁcally,
gamma aminobutyric acid b receptor 1 (GABBR1) (rs29232; pcombined ¼ 8.973 1017) and HLA-F (rs3129055 and rs9258122; pcombined ¼
7.36 3 1011 and 3.33 3 1010, respectively). Notably, the association of rs29232 remained signiﬁcant (residual p < 5 3 104) after
adjustment for age, gender, and HLA-related SNPs. Furthermore, higher GABAB receptor 1 expression levels can be found in the tumor
cells in comparison to the adjacent epithelial cells (p < 0.001) in NPC biopsies, implying a biological role of GABBR1 in NPC carcino-
genesis. To our knowledge, it is the ﬁrst GWAS report of NPC showing that multiple loci (HLA-A, HLA-F, and GABBR1) within chromo-
some 6p21.3 are associated with NPC. Although some of these relationships may be attributed to linkage disequilibrium between the
loci, the ﬁndings clearly provide a fresh direction for the study of NPC development.Introduction
Nasopharyngeal carcinoma (NPC [MIM 161550]), arising
in the epithelium of the nasopharynx, is a multifactorial
malignancy associated with both genetic and environ-
mental factors. For example, NPC incidence exhibits
remarkable geographic and ethnic distribution; it is more
prominent in the southeast Asian regions, including
southern China, Hong Kong, and Taiwan, where the
annual incidence rate is approximately 25-fold higher
than that in the Western world.1 Moreover, NPC is
consistently associated with Epstein-Barr virus (EBV)
infection,2 and the clonal EBV DNA sequence can be
detected in tumor cells of patients in endemic areas.
Nevertheless, elevated NPC risk associated with EBV
infection is largely conﬁned to individuals of southern
Chinese origin.3 These ﬁndings suggest that genetic
factors act alone or via interactions with environmental
factors, such as EBV, to regulate NPC tumor formation
and progression.4–6
Association studies within the NPC endemic population
disclose that tumor susceptibility is associated with HLA
types.7 Increased risk of NPC was observed in individuals194 The American Journal of Human Genetics 85, 194–203, Augustwith the HLA-A2 allele, particularly HLA-A*0207.8 Other
variants linked to NPC include those in DNA repair genes,
such as X-ray repair cross-complementing group 1 (XRCC1
[MIM 194360]) and 8-oxoguanine glycosylase 1 (hOGG1
[MIM 601982]),9 as well as cytochrome P450 2E1
(CYP2E1 [MIM 124040])10 and glutathione S-transferase
M1 (GSTM1 [MIM 138350]), which function in the metab-
olism or detoxiﬁcation of nitrosamines and related carcin-
ogens.11 However, some of these reported associations
are not replicated in NPC patients within the Taiwanese
population.12
Previous analyses on NPC susceptibility genes were per-
formed via linkage studies or candidate-gene approaches.
Here, we conduct a genome-wide association study
(GWAS) to comprehensively examine the entire genome
with increased resolution and power. We report multiple
NPC-associated loci in the major histocompatibility
complex (MHC) region and replication of these ﬁndings
in two independent sets of case-control samples. After
adjustment by age, gender and other signiﬁcant SNPs,
our results clearly suggest that in addition to the HLA-A
gene, GABBR1 (MIM 603540) plays a role in the etiology
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Subjects and Methods
Study Subjects
Between August 1983 andMarch 2008, a cohort consisting of 4802
NPC patients from the northern parts of Taiwan, including Taipei,
Keelung, Taoyuan, Hsinchu, and Miaoli areas, was recruited upon
initial diagnosis at the Chang Gung Memorial Hospital (CGMH)
at Linkou (Taoyuan County, Taiwan). Among these patients,
3493were excludedbecauseof the following reasons: lack of biopsy
at CGMH (1573 cases); nontreatment at the Department of Radia-
tion Oncology, CGMH at Linkou (619 cases); or refusal to donate
blood (1301 cases). All samples (n ¼ 918) were randomly selected
from1309 cases and categorized into three stages. Histological clas-
siﬁcation was performed according to the World Health Organiza-
tion (WHO) criteria,13 and pathology records were reviewed for
conﬁrmation of NPC diagnosis. Additionally, stage, treatment,
follow-up status, and limited information on family history were
collected from hospital tumor registries and medical charts.
Healthy controls were recruited from local residents of Taoyuan
County through a project designated ‘‘Integrated Delivery System
of Health Screening, Taoyuan, Taiwan’’ by Chang Gung Univer-
sity, CGMH, and the Health Bureau of Taoyuan County, Taiwan.
In total, 11,196 samples (8077 males and 6119 females) were
collected from May 2007 to Dec 2007. Control samples were
randomly selected according to male/female ratio and age distri-
bution. Controls affected by any type of cancer andwith a personal
family history of NPC were excluded. All cases and controls were
of a homogeneous Han Chinese origin.
In brief, the ﬁrst group comprised 288 NPC cases (214 male and
74 female) and 297 controls (199 males and 98 females). Three
hundred and thirty-nine NPC patients (232 males and 107
females) and 696 controls (544 males and 152 females) were
included in stage II genotyping. The third independent sample
group consisted of 296 cases (232 males and 64 females) and
944 controls (657 males and 287 females).
This study was reviewed and approved by the institutional
review board and ethics committee of CGMH. Informed consent
was obtained from all study participants. Demographics of the
case and control samples for statistical analyses are provided in
Table S1, available online.
Genotyping
Illumina Infinium Genotyping
Blood samples were collected at the time of enrollment, and
genomicDNAwasobtainedwith theuseof aDNAisolationkit (Qia-
gen,Valencia, CA,USA). Thequality and concentrationof genomic
DNA for each sample fulﬁlled the requirements for GWAS recom-
mended for the Illumina Inﬁnium platform. Genome-wide
genotyping experiments using 600 Hap550v3_A BeadChips were
outsourced to the Illumina-certiﬁed service provider, Genizon
Biosciences (Genizon BioSciences, Canada).
ABI TaqMan Genotyping
ABI TaqMan technology was used for determining the genotype of
target SNPs in stage II and III experiments. Candidate SNPs were
examined with the use of a commercially available TaqMan SNP
genotyping assay kit and GeneAmp PCR System 9700 (Applied
Biosystems, Foster City, CA, USA), in accordance with the manu-
facturer’s instructions. The sequence detection software provided
by ABI was used for genotyping analysis. Two template-free
controls and six DNA samples of known genotype were included
in each plate as negative and positive controls, respectively.The AmeriSo that genotyping quality was ensured, duplicate samples were
included at different stages and the laboratory technicians were
blind to the affection status and quality control samples. For the
Illumina Inﬁnium platform, in addition to the four CEPH controls
included in each 96-well plate provided by the genotyping service
provider, 15 out of 585 samples were genotyped twice. The concor-
dance rate for duplicated genotyping was 99.99%. For the ABI
TaqMan platform, 40 samples were genotyped twice in stage II
and III experiments. The concordance rate for duplicated genotyp-
ing was 100%. The concordance rate for the 33 duplicated samples
was 98.65% for genotyping controls between the Inﬁnium and
TaqMan platforms.
Sample Quality Control
Genotypingwas attempted on 288 cases and 297 controls. In total,
23 samples failed the quality control assessments and were thus
removed. Two samples (one case andone control)werenot assessed
because of their low call rate (< 99%). One case that did not match
the gender predicted via the gender estimation function of Bead-
Studio was removed. Population stratiﬁcation within samples was
tested via the PLINK tool (v1.04).14 Pairwise identity-by-state
(IBS) distances were calculated for examination of the existence
of group differences. The permutation test for IBS differences
between groups suggests that study samples came from the same
group (data not shown). We also used genotype similarities imple-
mented in PLINK to identify individuals deviating by more than
four standard deviations (SD) from other study subjects. Two case
samples regarded as genetic outliers were excluded from the
following statistical analyses. Furthermore, cryptic relatedness
between study participants was examined by estimating IBD. Pairs
of DNA samples showing PI-HAT > 0.2 (estimated proportion of
IBD alleles) were individually inspected, and ﬁve controls and
one case were excluded. Next, we used the inbreeding coefﬁcient
(F), which compares the observed versus expected number of
homozygous genotypes within an individual, to test whether gen-
otyping contamination or extreme outbreeding exists in our
samples. No samples were excluded for this test (cutoff F < 0.1),
because the results of contamination evaluation were negative.
Lastly, we computed the principal components to adjust for popu-
lation stratiﬁcation, using the EIGENSOFT package.15 Six cases and
six controls were removed as outliers, because they exceeded 6 SD
along one of the six top principal components. After outliers were
excluded, case and control individuals largely overlapped and
were distributed in a similar pattern, indicating that cases and
controls were from the same population.
SNP Quality Control
For Illumina BeadChip genotyping, preliminary SNP quality
control was assessed by the genotyping service provider, including
call frequency (< 0.98), cluster separation (< 0.27), heterozygosity
cluster intensity mean (< 0.15), allelic intensity ratio for SNPs on
chromosome X in males (< 0.005), SNPs with one or more parent-
child non-Mendelian error or replication errors (R 1), and Hardy-
Weinberg equilibrium (HWE) (< 0.0005). Among the 561,466
SNPs, 7864 were rejected. Furthermore, 7347 SNPs with heterozy-
gous haploid genotypes and 80,910 SNPs with minor allele
frequency (MAF) < 1% were excluded. As a result, 480,365 SNPs
were included for further statistical analysis.
In stage II and III experiments, the average call rate per sample
was > 98% and the average call rate per SNP was > 98%. We elim-
inated three SNPs with HWE < 0.005 or MAF < 0.01 in stage IIcan Journal of Human Genetics 85, 194–203, August 14, 2009 195
experiments and 12 such SNPs in stage III experiments, leaving 34
stage II and 39 stage III SNPs for statistical analysis.
Association and Statistical Analysis
Single-SNP Analysis
For the initial scan, we analyzed each single locus via allelic-based
logistic regression with an additive logistic model to obtain the
pvalue, odds ratio (OR), and95%conﬁdence interval (CI) inPLINK.
Both age and gender were included as covariates in the logistic
regression analysis. To address the issue ofmultiple testing, we per-
formed an adaptive permutation test of case-control status and
analysis 10,000 times. All association data were calculated with
PLINK, with the exception of those in Figure S3, which were calcu-
latedwithHelixTree software v 6.4.2, (GoldenHelix, Bozeman,MT,
USA). After an initial genotyping quality check, a quantile-quantile
plot (Q-Qplot) of the chi-square statistic values (with the use of the
inverse chi-square distribution with one degree of freedom [df])
against their expectations under the null hypothesis was used for
estimating a lambda (l) inﬂation factor that indicates whether
systematic bias is present. TheQ-Qplot and l valuewere calculated
with the snpMatrix of R package version 2.8.0.16 We applied the
0.025 and 0.975 quantiles of beta approximation for distribution
of the statistic under thenull hypothesis of independence to obtain
pointwise conﬁdence bounds (Figure S2). The genomic control
parameter l value was 1.039362, suggesting the absence of major
population structure associated with case-control status.
Haplotype Analysis
In addition to single-SNP analysis, we performed allelic-based
logistic regression analysis with the use of HelixTree software, fol-
lowed by genome-wide haplotype analysis with the use of a haplo-
type trend regression algorithm ﬁtted to amodel of additive effects
of haplotypes. Analyses were performed with the use of sliding
window sizes of 5, 9, and 13 contiguous markers. Haplotype fre-
quencies for each individual were estimated with the use of an ex-
pectation-maximization (EM) algorithm.Theminimumhaplotype
frequency was set at 0.01, and haplotypes with frequencies below
this threshold were binned together into a combined group.
Multivariate and Stepwise Logistic Regression Analysis
For examination of the residual effect of one SNP after adjustment
with another SNP,multivariate logistic regressionanalyses between
12 signiﬁcant SNPs located at chromosome 6p21.3 in a combined
data set (stage I þ stage II) were performed in PLINK, and age and
gender were introduced as covariates. The same approach was per-
formed for examinationof the residual effect of 12 signiﬁcant SNPs,
withHLA-A*0207/0215NandHLA-A*110101/1121Nallelesused as
covariates. Stepwise logistic regression analysis, including HLA-A*
0207/0215N, HLA-A*110101/1121N, age, gender, and 12 signif-
icant SNPs used as explanatory variables, was performed with SAS
software v 9.0 (SAS Institute, Gary, NC, USA).
Linkage Disequilibrium Analysis
Genotyping results of 285 healthy control samples were used in
the stage I experiment for calculating linkage disequilibrium
(LD) between the ‘‘associated’’ SNPs. The region of chromosome
6p21 was examined with the Haploview package17 for patterns
of LD and identiﬁcation of haplotype blocks.
Imputation
Imputation for selectionof SNPs in the stage III experimentwasper-
formedwith theuse of IMPUTEv0.3.2,18 basedonHapMapPhase II
haplotypes, and was further evaluated with SNPTEST (v1.1.4).19196 The American Journal of Human Genetics 85, 194–203, August 1Resequencing of the GABBR1 Flanking Region
Thirty-seven NPC samples with high-risk haplotypes, as well as 48
healthycontrols,were selected for resequencingwith a view toﬁne-
mapping the GABBR1 ﬂanking region. Primers were designed for
ampliﬁcation of a 45.9 kb genomic region covering the upstream,
coding, and downstream regions of the GABBR1 gene. Sequences
were derived by direct sequencing of PCR products with the ABI
3730 DNA analyzer, in accordance with the manufacturer’s
protocols. Bidirectionally sequenced trace ﬁles were analyzed
with Mutation Surveyor v3.13 (SoftGenetics, PA, USA). Variants
with MAF >1% were scored for chi-square analysis (Figure S4).
Four SNPs (ss120095059, ss120095075, ss120095079, and
ss120095083) identiﬁed with the aid of resequencing have now
been submitted to NCBI dbSNP.
Expression Analyses
Immunohistochemical Staining
Immunohistochemical staining procedures were performed as
described previously.20 A GABAB receptor 1 monoclonal antibody
(raised against a peptide shared by GABAB R1a and GABAB R1b,
and therefore recognizing both isoforms; clone 2D7, Abnova, Tai-
pei, Taiwan) and a GAD67 rabbit polyclonal antibody (RB-10251,
Thermo Fisher Scientiﬁc, Cheshire, UK) were used. Images of
stained slides were obtained via the ScanScope CTautomated slide
scanning system (Aperio Technologies, Vista, CA, USA) and evalu-
atedbyexperiencedpathologists.The intensityofGABABreceptor1
signal in tumor cells and adjacent epithelial cells in each biopsy
sample was compared with the Wilcoxon signed-ranks test in the
SPSS software version 13.0 (SPSS, Chicago, IL, USA).
EBER In Situ Hybridization
In situ hybridization (ISH) for detecting EBV-encoded RNA tran-
scripts (EBERs) was performed with the use of the EBV Probe ISH
Kit (Novocastra, Newcastle, UK), in accordance with the manufac-
turer’s instructions.
Cell Culture
BM1 was cultured in DMEM containing 10% fetal bovine serum
(FBS). The NPC (HK1) and normal nasopharyngeal epithelial
(NP69) cell lines were kindly provided by Sai-Wah Tsao (Depart-
ment of Anatomy, University of Hong Kong, P.R. China). HK1
was maintained in RPMI 1640 containing 10% FBS, and NP69
was cultured in deﬁned keratinocyte-SFM medium (Invitrogen,
Carlsbad, CA, USA). All cells were cultured at 37C in a 5% CO2
incubator.
RNA Extraction and Reverse Transcription-Polymerase Chain Reaction
Total RNA extraction, reverse transcription-polymerase chain reac-
tion (RT-PCR), and real-time PCR reactions were performed as
described previously.21 For the real-time PCR experiment, the
GABBR1 gene-speciﬁc primers (RT-F, 50-GCTGGGAAGAACATGC
TATC-30; and RT-R, 50-CTTCAAGCCAGGTACGAACT-30) were
used, and GAPDH was employed as an internal control.
Immunoblotting
Immunoblotting fordetectionofGABAB receptor1proteinwasper-
formed as described previously,21 with the use of a GABAB receptor
1 monoclonal antibody (clone 2D7, Abnova, Taipei, Taiwan).
Sequence-Based HLA Typing
A total of 244 NPC cases and 228 controls were randomly selected
from the stage I GWAS sample. HLA-A alleles were typed by
directly sequencing the region covering exons 2 and 3 of the
HLA-A gene.22 All sequences were assembled and compared with
the NCBI dbMHC database23 for identiﬁcation of the HLA-A4, 2009
Figure 1. Summary of GWAS Results,
Based on Chromosome
Associations with NPC were determined
for 480,365 SNPs among 277 cases and
285 controls. The x axis represents the
position on each chromosome from the p
terminus to the q terminus, and the y
axis depicts p values on a minus logarith-
mic scale. Analysis was adjusted for age
and gender with the use of a logistic regres-
sion model. Chromosomes are shown in
alternating colors for clarity. Red dots indi-
cate SNPs with signiﬁcant p values in the
combined data from three stages (Table 1).
Data on the X chromosome are not pre-
sented, due to gender adjustment during
statistical analysis.genotype. Because polymorphisms outside exons 2 and 3 were not
analyzed, some groups of alleles with sequence differences in the
other exons could not be determined in this study. In such cases,
an abbreviation of some allele group was assigned, on the basis of
the IMGT/HLA Ambiguous Allele Combinations File24 (release
2.25.2, 4/17/2009). Statistical analysis was performed with the
use of the R script. Allele frequencies were computed between
cases and controls and accessed with the chi-square test (df ¼ 1)
or Fisher’s exact test at an expected cell count of < 5. All statistical
tests were two-sided.
Results
Genome-wide Screening of NPC-Associated SNP
Markers
We initially genotyped 561,466 SNPs in 288 NPC cases and
297 healthy controls (stage I; Table S1) collected from the
CGMH at Linkou, Taoyuan, and community hospitals of
Taoyuan County. Stringent quality control criteria were
applied to all of the samples and SNP markers tested. A
total of 11 cases and 12 controls were removed because
of low call rates (< 99%), identity problems, and failure
in IBD or principle components analysis (PCA) genetic-
outlier tests. In terms of SNP markers, 81,101 SNPs were
eliminated after a series of quality control steps (Figure S1).
The ﬁnal GWA analysis was performed on 480,365 SNPs in
277 cases and 285 controls. Disease association was
systematically tested across the genome with the logistic
regression module in PLINK (see Subjects and Methods),
and several putative association regions for NPC were
detected. The distribution of p values was similar to the
expected distribution (the estimated genomic control
parameter was 1.039), implying no systematic increase in
false-positive ﬁndings as a result of population stratiﬁca-
tion or other sources of bias (Figure S2). Furthermore, we
assessed the signiﬁcance level of SNPs by using 10,000
permutations. Among the 480,365 SNPs, 15 signiﬁcant
SNP markers, located at chromosomes 6, 13, and 20, withThe Amerinominal p values (adjusted for age and gender) of < 5 3
105, were identiﬁed (Figure 1 and Table S2).
For further evaluation of GWAS data, genome-wide
single-marker analysis was performed with HelixTree soft-
ware. Similar to the results obtained with PLINK, SNP
markers close to the GABBR1, HLA-A (MIM 142800), and
HLA complex group 9 (HCG9) genes were signiﬁcant. In
addition, haplotype analysis revealed signiﬁcant associa-
tions in the same chromosome 6p21.3 region (Figure S3),
further supporting our single-SNP association results.
Two additional regions in close proximity to HLA-F (MIM
143110), ﬂotillin 1 (FLOT [MIM 606998]), and immediate
early response 3 (IER3 [MIM 602996]) genes, which
exhibited low signiﬁcance in single-SNP analysis, were
statistically signiﬁcant in haplotype analysis (Table S2).
Validation of Signiﬁcant Markers in the Second Group
of Case-Control Samples
To validate the GWAS ﬁndings, we genotyped 33 SNPs with
the most signiﬁcant p values (15 from single-marker anal-
ysis and 18 from haplotype analysis; Table S2) in an inde-
pendent set of case-control samples (stage II), including
339 NPC cases and 696 controls, using the TaqMan assay.
Twelve out of 33 SNPs were signiﬁcantly linked to NPC
susceptibility (with pcombined IþII < 5 3 10
5) and mapped
to a 430 kb region containing the GABBR1, HLA-F, HLA-A,
and HCG9 genes on chromosome 6p21.3 (rs2267633–
rs16896923) (Figure 2 and Table 1). One of the most signif-
icant SNPs (rs29232; (pcombined I þ II ¼ 9.60 3 1012, OR ¼
1.71, 95% CI ¼1.46~1.99) and three other markers
(rs29230, rs2076483, and rs2267633) were located close to
or within the GABBR1 gene. Two other strongly associated
markers, rs2517713 and rs2975042 (Pcombined IþII ¼ 5.54 3
1012 and 1.57 3 1011, respectively), were located down-
stream of the HLA-A gene. Two associated SNPs
(rs3129055 and rs9258122) were identiﬁed in the upstream
regulatory region of the HLA-F gene, and four (rs9260734,can Journal of Human Genetics 85, 194–203, August 14, 2009 197
Figure 2. Association Analyses of SNPs at Chromosome 6p21.3
Top: Blue dots indicate the p values for association testing drawn from ﬁrst-stage GWAS on a minus logarithmic scale. Red dots depict
SNPs with signiﬁcant p values in combined (three stages) data. Bottom: Detailed LD structure depicted in HaploView. Analysis was
adjusted for age and gender with the use of a logistic regression model. The corresponding location of genes is shown below. Pairwise
linkage disequilibrium estimated in 285 control samples depicted in HaploView is shown at the bottom. Increasing intensities of red
represent higher r2 values.rs3869062, rs5009448, and rs16896923) were identiﬁed in
the HCG9 gene region. Our results show that (1) the four
associated SNPs in the HCG9 gene are in strong LD (r2 ¼
0.8; Table S3) with those located in the HLA-A gene, (2) no
residual effects of SNPs of HCG9 are detected after adjust-
ment with SNPs in HLA-A genes (Table 2), and (3) the
HLA-Agene is closely associatedwithNPCsusceptibility.7,25
Thus, we conclude that the association signals observed in
the HCG9 gene are primarily due to the effects of HLA-A.
Validation of Genetic Variations in the GABBR1 Gene
in Relation to NPC Susceptibility
To our knowledge, this is the ﬁrst study to show an associ-
ation between the genetic variants of the GABBR1 gene
and NPC. SNP rs29232 is located at the upstream regula-
tory region (10571) of GABBR1 or ~306 kb telomeric to
the two signiﬁcant markers found in the HLA-A gene. In
contrast to HCG9, rs29232 was in moderate LD (r2 ¼ 0.3)
with SNPs located in HLA-A, ascertained on the basis of
the LD map built from the 285 control samples in stage I
analysis (Table S3). To investigate whether the association198 The American Journal of Human Genetics 85, 194–203, Augustdetected with the GABBR1 gene is independent of HLA-A
signals, we carried out multivariate logistic regression
analysis, using other signiﬁcant SNPs as covariates. After
adjustment for signiﬁcant SNPs close to the HLA-A
gene (rs2975042 and rs2517713), only rs29232 SNP in
the GABBR1 gene retained signiﬁcance (pcombined I þ II ¼
3.52 3 104 and 1.41 3 103; Table 2), and vice versa
(pcombined I þ II ¼ 5.72 3 104 and 2.57 3 104).
We also performed a sequence-based typing approach to
determine theHLA-A allele inour samplesused in the stage I
(GWAS) experiment (228 controls and 244 cases; see Table
S4), with a view to interpreting our ﬁndings in the light of
HLA typing information. Similar to previous ﬁndings,8
the allele frequency of A*0207/0215N was signiﬁcantly
higher (p ¼ 2.28 3 106) in NPC patients in comparison
to controls, whereas the frequency of A*110101/1121N
was markedly lower in NPC patients (p ¼ 1.88 3 103).
Accordingly, we included age, gender, A*0207/0215N,
and/or A*110101/1121N as covariates for multivariate
logistic regression analysis. Association of rs29232,
rs2517713, and rs2975042 with NPC susceptibility14, 2009
Table 1. Significant SNPs Identified through GWAS and Located at Chromosome 6p21.3
Risk Allele Freq.b
SNPa Chr.
Risk
Allele Case Control OR (95% CI)b
Stage I
p Value
Stage II
p Value
Stage III
p Value
Combined
p Value
Nearest
Gene
rs2517713 6 A 0.763 0.622 1.88 (1.65–2.15) 3.56E08*** 2.61E05*** 4.07E10*** 3.90E20*** HLA-A
rs2975042 6 A 0.759 0.621 1.86 (1.63–2.13) 2.54E08*** 9.21E05*** 7.78E10*** 1.60E19*** HLA-A
rs9260734 6 G 0.782 0.658 1.85 (1.61–2.12) 2.49E07*** 6.29E04** 6.14E10*** 6.77E18*** HCG9
rs29232 6 A 0.586 0.456 1.67 (1.48–1.88) 1.39E08*** 4.52E05*** 1.34E07*** 8.97E17*** GABBR1
rs3869062 6 A 0.792 0.683 1.78 (1.55–2.05) 1.58E06*** 8.13E04** 6.47E09*** 8.68E16*** HCG9
rs5009448 6 G 0.750 0.637 1.72 (1.51–1.96) 9.41E06*** 6.44E04** 1.38E09*** 1.30E15*** HCG9
rs3129055 6 G 0.406 0.312 1.51 (1.34–1.71) 2.24E04** 6.28E03* 1.59E06 *** 7.36E11*** HLA-F
rs9258122 6 A 0.406 0.315 1.49 (1.32–1.69) 2.24E04** 2.02E02* 7.32E07 *** 3.33E10*** HLA-F
rs16896923 6 A 0.850 0.768 1.66 (1.42–1.94) 5.63E06*** 2.29E03* 2.66E05 *** 2.49E10*** HCG9
rs2267633 6 A 0.821 0.741 1.57 (1.36–1.82) 2.86E05*** 4.17E02 2.82E05 *** 1.28E09*** GABBR1
rs2076483 6 A 0.821 0.741 1.57 (1.36–1.82) 2.86E05*** 3.85E02 3.13E05 *** 1.49E09*** GABBR1
rs29230 6 A 0.819 0.743 1.56 (1.34–1.80) 3.99E05** 5.76E02 4.03E05 *** 4.77E09*** GABBR1
a Significant SNPs identified from GWAS (stage I) and validated by two independent sets of case-control samples (stage II and III). Analysis was adjusted for age
and gender with the use of a logistic regression model.
b Risk allele frequencies and odds ratios (OR) were calculated on the basis of combined samples.
* Permuted p value < 0.01. All permuted p values were computed with 10,000 permutations. For detailed information on assays, see Tables S2 and S7.
** Permuted p value < 0.001. All permuted p values were computed with 10,000 permutations. For detailed information on assays, see Tables S2 and S7.
*** Permuted p value < 0.0001. All permuted p values were computed with 10,000 permutations. For detailed information on assays, see Tables S2 and S7.remained signiﬁcant (p < 5 3 104), even when condi-
tioned by A*0207/0215N, A*110101/1121N, or both (Table
S5). Stepwise logistic regression analysis26 was also per-
formed in the same data set by including age, gender,
A*0207/0215N, A*110101/1121N, and 12 signiﬁcant SNPs
as explanatory variables. As shown in Table S6, the ﬁnal
model included A*0207/0215N, rs2975042 (HLA-A),
rs3129055 (HLA-F), gender, and rs29232 (GABBR1), sug-
gesting that rs29232 is independent of HLA-A effects. On
the basis of these results, we suggest that the HLA-A gene
alone does not fully account for the association between
NPC and the MHC region on chromosome 6. In keeping
with a previous linkage study implying that an unknown
gene closely linked to the HLA locus confers increased risk
of NPC,27 our data further suggest that genetic variants in
or close to the GABBR1 gene are potential risk variants.
Fine Mapping of GABBR1 by Resequencing
and Identiﬁcation of Additional Signiﬁcant SNPs
Given the detection of a very strong signal (rs29232)
upstream of GABBR1, genomic regions encompassing the
regulatory and coding regions of GABBR1 in 37 NPC cases
with high-risk haplotypes (identiﬁed from GWAS) and 48
randomly selected controlswere resequenced for identiﬁca-
tion of the mutations and variants associated with NPC
susceptibility. No mutations were detected in the rese-
quencing region (datanot shown), and22 additional signif-
icant SNPs were individually identiﬁed in the upstream,
intron, and downstream regions (p < 5 3 107, chi-square
test), as shown in Figure S4.The AmerFurther Validation of Signiﬁcant SNPs with a Third
Group of Samples
To further validate our results in the Taiwanese population
and ﬁnemap the 6p21.3 region, we examined 51 SNPs that
were: (1) signiﬁcant in combined data of stage I and stage II
experiments, (2) identiﬁed from GABBR1 gene region rese-
quencing; and (3) potentially functional, in that they were
selected by imputation and found to be located in loci
including GABBR1, HLA-F, and HLA-A/HCG-9 (see Subjects
and Methods), in the third independent group consisting
of 296 cases and 944 controls (stage III). Twelve SNPs
were excluded from subsequent analysis as a result of
failure of the quality control check. As shown in Table 1
and Table S7, 23 among the 39 SNPs were signiﬁcant,
with a p value < 5 3 105. Among these SNPs, nine were
located in GABBR1, six in HLA-F, and eight in the HLA-A/
HCG9 gene regions. More importantly, the observed asso-
ciation of the 12 SNPs identiﬁed in GWAS was replicated.
The issue of whether these variants can modulate GABBR1
expression levels or alternative splicing requires further
investigation. Collectively, the stage III genotyping results
further support the theory that genetic variants located in
the GABBR1, HLA-F, and HLA-A/HCG9 loci are strongly
associated with NPC susceptibility.
Expression of GABAB Receptor 1 and GABA
Biosynthetic Enzyme, GAD, in NPC Tumor Cells
GWAS and replication results indicate that GABBR1 is
a potential susceptibility gene for NPC. This prompted us
to investigate the plausibility that this gene is biologicallyican Journal of Human Genetics 85, 194–203, August 14, 2009 199
Table 2. Multivariate Logistic Regression Analysis for Significant SNPs at Chromosome 6p21.3
p Value of SNP 1 Adjusted for SNP 2a
GABBR1 HLA-F HLA-A HCG9               SNP1
SNP2 rs2267633 rs2076483 rs29230 rs29232 rs3129055 rs9258122 rs2517713 rs2975042 rs9260734 rs3869062 rs5009448 rs16896923
rs2267633 NA NA NA 5.23E−08 1.14E−03 3.69E−03 7.16E−07 2.59E−07 9.48E−06 3.94E−05 9.10E−05 5.10E−04
rs2076483 NA NA NA 5.03E−08 1.12E−03 3.89E−03 6.58E−07 2.38E−07 9.29E−06 2.92E−05 8.62E−05 4.52E−04
rs29230 NA NA NA 3.54E−08 1.25E−03 3.63E−03 3.49E−07 1.20E−07 8.33E−06 4.91E−05 7.91E−05 5.77E−04
GABBR1
rs29232 2.63E−01 2.63E−01 3.60E−01 NA 4.62E−01 3.43E−01 2.57E−04 5.72E−04 4.60E−03 1.42E−02 1.26E−02 2.53E−02
rs3129055 2.75E−03 2.64E−03 4.44E−03 1.33E−08 NA NA 8.71E−09 1.84E−08 1.14E−06 4.91E−06 2.17E−05 1.74E−04
HLA-F
rs9258122 2.05E−03 2.10E−03 3.61E−03 2.64E−08 NA NA 1.13E−08 1.94E−08 1.55E−06 4.70E−06 2.81E−05 1.15E−04
rs2517713 9.01E−01 8.99E−01 9.07E−01 1.41E−03 9.70E−02 1.72E−01 NA NA 6.52E−01 2.46E−01 8.31E−01 7.33E−01
HLA-A
rs2975042 8.24E−01 8.42E−01 6.42E−01 3.52E−04 8.38E−02 1.56E−01 NA NA 9.18E−01 8.98E−01 7.00E−01 8.18E−01
rs9260734 3.36E−01 3.31E−01 3.95E−01 2.14E−05 2.17E−02 4.71E−02 1.75E−03 3.72E−03 NA 7.83E−01 6.48E−01 6.98E−01
rs3869062 3.19E−01 3.22E−01 3.54E−01 8.03E−06 1.10E−02 2.59E−02 1.02E−04 1.46E−03 1.60E−01 NA 3.94E−01 7.46E−01
rs5009448 1.00E−02 1.02E−02 1.37E−01 1.23E−06 2.47E−02 5.34E−02 1.18E−05 7.91E−05 3.58E−03 1.87E−02 NA 1.11E−01
HCG9
rs16896923 7.94E−03 7.21E−03 1.11E−02 1.19E−07 8.78E−04 2.67E−03 4.21E−07 3.00E−06 2.21E−04 9.23E−04 2.47E−03 NA
a Multivariate logistic analysis was performed. We used the combined stage I and stage II data sets in PLINK were used to examine the residual effects of SNP 1
while using SNP 2 as a covariate, and we adjusted the results for age and gender. SNPs with an adjusted p value < 0.01 are highlighted in bold.related to NPC risk. GABBR1 encodes a protein denoted
GABAB receptor 1, a G protein-coupled receptor that
forms a heterodimer with GABAB receptor 2, triggering
downstream signaling events in response to binding
of the ligand, gamma-aminobutyric acid (GABA). The
GABAergic system possibly plays a role in proliferation,
differentiation, and migration of cancer cells.28 Expression
levels of GABA and its biosynthetic enzyme, GAD67, are
signiﬁcantly increased in several neoplastic tissues, such
as colorectal carcinoma,29 breast cancer,30 gastric cancer,31
and prostate cancer.32 However, similar analyses have not
been performed in NPC. Accordingly, the expression and
distribution of GABAB receptor 1 protein and glutamate
decarboxylase (GAD67) were evaluated in 146 NPC biop-
sies randomly selected from the CGMH tumor bank with
the use of immunohistochemical staining. Positive signals
of the GABAB receptor 1 protein were detected in more
than 77% (113 out of 146) of the biopsies tested. GABAB
receptor 1 protein was identiﬁed in NPC tumor cells, as
observed from EBV-encoded RNAs (EBERs; Figure 3B).
Adjacent normal nasopharynx epithelial cells were identi-
ﬁed in 100 of 146 NPC biopsies, and GABAB receptor 1
protein 1 was detected in 71 cases (71%). The intensity
of the GABAB receptor 1 signal in tumor cells was signiﬁ-
cantly higher than that detected in adjacent normal
epithelial cells (p < 0.001; details shown in Table S8).
Interestingly, we found that inﬁltrated leukocytes and
endothelial cells also express GABAB receptor 1 protein
(Figures 3C and 3D). Notably, GAD67 was also detected
in tumor cells (Figure S5), indicating that NPC tumor cells
secrete GABA, which may exert its effects on tumor cells200 The American Journal of Human Genetics 85, 194–203, August 1via the autocrine pathway or on surrounding cells via the
paracrine pathway.
NPC Tumor Cell Lines Express GABAB Receptor 1
Protein
We also examined the GABBR1 transcript and protein
levels in NPC cell lines and in an immortalized nasopha-
ryngeal epithelial cell line (NP69), using RT-PCR (Figure 3E)
and immunolotting (Figure 3F). One NPC cell line (BM1)
was established from NPC patients from Taiwan and the
other (HK1) from NPC patients from Hong Kong. Both
cell lines expressed GABBR1 transcripts and protein. BM1
and HK1 cells contained the AA genotype at rs29232,
whereas NP69 carried the AG genotype. Although the
relationship between risk allele ‘‘A’’ of rs29232 and
gene expression levels remains to be elucidated, we specu-
late that GABAergic systems are involved in NPC tumor
cell proliferation, angiogenesis, or immunomodulation
processes. Further investigation is essential for clear estab-
lishment of the relationship between GABBR1 and NPC
development.
Discussion
We applied the GWA approach to identify loci associated
with NPC within the Taiwanese population. Initially, we
identiﬁed 33 NPC-associated genetic variants by using a
relatively small case-control set, and we replicated the ﬁnd-
ings in a second independent case-control set of samples.
Loci within three different genes (GABBR1, HLA-F, and
HLA-A) in the chromosome 6p21.3 region were associated4, 2009
Figure 3. GABAB Receptor 1 Protein Expression in NPC Tumor Cells
GABAB receptor 1 protein was detected in NPC tumor cells (A), inﬁltrating leukocytes (C, indicated by arrowheads), and endothelial cells
(D, indicated by ‘‘V’’) by immunohistochemical staining. Distribution of NPC tumor cells is depicted with positive nuclear EBER signals
(B). Expression of GABBR1 transcripts (E) and protein (F) was detected in NPC cell lines and in the normal nasopharyngeal epithelial cell
line, NP69.with NPC susceptibility. The contribution of each locus
was examined by multivariate and stepwise logistic regres-
sion analyses, which showed that GABBR1 is an indepen-
dent risk factor. In view of this ﬁnding, we resequenced
the GABBR1 gene region, revealing 22 additional NPC-
associated SNPs. The putative associations of these SNPs,
as well as those identiﬁed via imputation methods, were
further validated in a third independent case-control set.
Finally, we evaluated the expression levels of GABBR1 in
NPC biopsies and cell lines, and we detected GABAB
receptor 1 protein in these samples.
The chromosome 6p21.3 region was previously mapped
as a NPC-susceptibility locus via the positional cloning
approach,33 and a region 132 kb in length covering the
HLA-A, HLA-B, HLA-C, and HLA-E loci is implicated in
NPC susceptibility in the Taiwanese population.34 In this
study, we employed a high-resolution SNP array platform
encompassing the entire genome, conﬁrmed the associa-
tion of this chromosomal region with NPC, and identiﬁed
speciﬁc SNPs within theHLA-A,HLA-F, and GABBR1 loci as
potentially important risk determinants.
Some NPC-associated risk loci identiﬁed in this study
were located in genes, such as HLA-A and HCG9, that are
reportedly associated with the development of EBV-associ-
ated Hodgkin lymphoma (HL [MIM 236000])35 and infec-
tious mononucleosis (IM) after primary EBV infection.36
These variants possibly alter disease progression after EBV
infection, thereby modulating EBV-related NPC risk.37
In addition to the HLA-A locus, HLA-F was associated
with NPC risk. The HLA-F protein is primarily retained
intracellularly in untransformed B cells but, intriguingly,
can be detected on the surface of EBV-transformed B
lymphoblastoid cell lines from the same individuals,38The Amerimplying a role of viral infection or transformation in
releasing HLA-F from the endoplasmic reticulum and
Golgi. A genome-wide gene expression proﬁling experi-
ment has revealed that downregulation of HLA-A, HCG9,
and HLA-F is correlated with EBV-encoded EBNA1 expres-
sion,39 further suggesting a potential association between
these HLA gene products and EBV infection.
Notably, we identiﬁed and conﬁrmed an association
in the GABBR1 gene in close proximity to a previously re-
ported NPC-susceptible microsatellite marker, D6S1624.40
The MHC region is characterized by extensive LD and
high polymorphisms. Because of the strong LD of the
entire HLA region, it is difﬁcult to ascertain whether the
association in GABBR1 is completely independent of those
identiﬁed in the HLA-A loci or whether any associated
locus is a functional determinant of NPC risk. However,
data from stepwise or multivariate logistic regression anal-
yses (Table 2, Tables S5 and S6), resequencing-based
discovery of additional NPC-associated SNPs in GABBR1
(Table S7), and GABAB receptor 1 protein expression data
from NPC biopsies and cell lines support the theory that
GABBR1 plays a functional role in the etiology of NPC.
There are some limitations to the interpretation of data
obtained in this study. GWAS generally suffers from dimin-
ished power as a result of the need to correct for multiple
comparisons when assessing statistical signiﬁcance. We
applied staged analysis with sequential replications tomiti-
gate this problem. Nevertheless, our initial case-control
sample was relatively small. Although we are able to iden-
tify a number of highly signiﬁcant associations (e.g., p <
105) and replicate them in independent case-control
sets, it is possible that some SNP associations with larger
p values, particularly those with larger effect sizes, are ofican Journal of Human Genetics 85, 194–203, August 14, 2009 201
greater biological importance than those identiﬁed here.
Therefore, genetic variants with marginal p values (e.g.,
104 to 105) are considered potential functional determi-
nants and should be further explored to obtain insights
into the molecular mechanisms underlying NPC carcino-
genesis. Future challenges include determination of the
molecular characteristics of the variants and their mecha-
nistic roles in NPC susceptibility. Another limitation of
this study is the lack of individual environmental exposure
data. This deﬁciency may have decreased our sensitivity in
detecting genetic associations, given thatwewere unable to
adjust for major environmental risk factors, and may have
precluded our ability to address questions related to gene-
environment interactions. Further large-scale, population-
based genetic epidemiologic studies of NPC with detailed
individual risk factor information, particularly EBV anti-
body titers, are essential for assessing and characterizing
the relative importance of genetic and environmental risk
factors in NPC susceptibility.
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